457 related articles for article (PubMed ID: 29590099)
1. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database.
Kumarendran B; O'Reilly MW; Manolopoulos KN; Toulis KA; Gokhale KM; Sitch AJ; Wijeyaratne CN; Coomarasamy A; Arlt W; Nirantharakumar K
PLoS Med; 2018 Mar; 15(3):e1002542. PubMed ID: 29590099
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.
Rocha ALL; Faria LC; Guimarães TCM; Moreira GV; Cândido AL; Couto CA; Reis FM
J Endocrinol Invest; 2017 Dec; 40(12):1279-1288. PubMed ID: 28612285
[TBL] [Abstract][Full Text] [Related]
4. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.
Ayonrinde OT; Adams LA; Doherty DA; Mori TA; Beilin LJ; Oddy WH; Hickey M; Sloboda DM; Olynyk JK; Hart R
J Gastroenterol Hepatol; 2016 May; 31(5):980-7. PubMed ID: 26589977
[TBL] [Abstract][Full Text] [Related]
5. High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance.
Cai J; Wu CH; Zhang Y; Wang YY; Xu WD; Lin TC; Li SX; Wang LH; Zheng J; Sun Y; Liu W; Tao T
Int J Obes (Lond); 2017 Sep; 41(9):1341-1347. PubMed ID: 28487551
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome.
Falzarano C; Lofton T; Osei-Ntansah A; Oliver T; Southward T; Stewart S; Andrisse S
J Clin Endocrinol Metab; 2022 Jan; 107(1):258-272. PubMed ID: 34491336
[TBL] [Abstract][Full Text] [Related]
7. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease.
Kim JJ; Kim D; Yim JY; Kang JH; Han KH; Kim SM; Hwang KR; Ku SY; Suh CS; Kim SH; Choi YM
Aliment Pharmacol Ther; 2017 Jun; 45(11):1403-1412. PubMed ID: 28370150
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of nonalcoholic fatty liver disease increased with type 2 diabetes mellitus in overweight/obese youth with polycystic ovary syndrome.
Patel-Sanchez N; Perito E; Tsai P; Raymond-Flesch M; Lodish M; Sarkar M
J Pediatr Endocrinol Metab; 2023 May; 36(5):441-446. PubMed ID: 37060356
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Paschou SA; Polyzos SA; Anagnostis P; Goulis DG; Kanaka-Gantenbein C; Lambrinoudaki I; Georgopoulos NA; Vryonidou A
Endocrine; 2020 Jan; 67(1):1-8. PubMed ID: 31538291
[TBL] [Abstract][Full Text] [Related]
10. Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease.
Vassilatou E; Vassiliadi DA; Salambasis K; Lazaridou H; Koutsomitopoulos N; Kelekis N; Kassanos D; Hadjidakis D; Dimitriadis G
Eur J Endocrinol; 2015 Dec; 173(6):739-47. PubMed ID: 26340970
[TBL] [Abstract][Full Text] [Related]
11. Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome.
Wang D; Nan N; Bing H; He B
Front Endocrinol (Lausanne); 2023; 14():1241734. PubMed ID: 37720537
[TBL] [Abstract][Full Text] [Related]
12. Increased COVID-19 infections in women with polycystic ovary syndrome: a population-based study.
Subramanian A; Anand A; Adderley NJ; Okoth K; Toulis KA; Gokhale K; Sainsbury C; O'Reilly MW; Arlt W; Nirantharakumar K
Eur J Endocrinol; 2021 May; 184(5):637-645. PubMed ID: 33635829
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome.
Shengir M; Krishnamurthy S; Ghali P; Deschenes M; Wong P; Chen T; Sebastiani G
World J Gastroenterol; 2020 Nov; 26(44):7046-7060. PubMed ID: 33311949
[TBL] [Abstract][Full Text] [Related]
14. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome.
Asfari MM; Sarmini MT; Baidoun F; Al-Khadra Y; Ezzaizi Y; Dasarathy S; McCullough A
BMJ Open Gastroenterol; 2020 Aug; 7(1):. PubMed ID: 32784205
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
Vassilatou E
World J Gastroenterol; 2014 Jul; 20(26):8351-63. PubMed ID: 25024594
[TBL] [Abstract][Full Text] [Related]
16. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome.
Vassilatou E; Lafoyianni S; Vryonidou A; Ioannidis D; Kosma L; Katsoulis K; Papavassiliou E; Tzavara I
Hum Reprod; 2010 Jan; 25(1):212-20. PubMed ID: 19887498
[TBL] [Abstract][Full Text] [Related]
17. Non-alcoholic fatty liver disease is associated with hyperandrogenism in women with polycystic ovary syndrome.
Hong SH; Sung YA; Hong YS; Song DK; Jung H; Jeong K; Chung H; Lee H
Sci Rep; 2023 Aug; 13(1):13397. PubMed ID: 37591864
[TBL] [Abstract][Full Text] [Related]
18. Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study.
Kumarendran B; O'Reilly MW; Subramanian A; Šumilo D; Toulis K; Gokhale KM; Wijeratne CN; Coomarasamy A; Tahrani AA; Azoulay L; Arlt W; Nirantharakumar K
Diabetes Care; 2021 Dec; 44(12):2758-2766. PubMed ID: 34649997
[TBL] [Abstract][Full Text] [Related]
19. Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features.
Daan NM; Jaspers L; Koster MP; Broekmans FJ; de Rijke YB; Franco OH; Laven JS; Kavousi M; Fauser BC
Hum Reprod; 2015 Oct; 30(10):2376-86. PubMed ID: 26269538
[TBL] [Abstract][Full Text] [Related]
20. A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease.
Dawson AJ; Sathyapalan T; Smithson JA; Vince RV; Coady AM; Ajjan R; Kilpatrick ES; Atkin SL
Clin Endocrinol (Oxf); 2014 Jun; 80(6):843-9. PubMed ID: 23746214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
